JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Want to cut your energy bills? Here’s how five experts are doing it 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
NEWARK, Calif., March 06, 2017 -- Depomed, Inc. (NASDAQ:DEPO) today announced that senior management will present at the following healthcare conferences during the month of March.
29th Annual ROTH Conference
Date: Monday, March 13, 2017
Time: 3:00 p.m. PDT
Location: Dana Point, CaliforniaOppenheimer 27th Annual Healthcare Conference
Date: Tuesday, March 21, 2017
Time: 8:30 a.m. EDT
Location: New York, New York
These presentations will be webcast live and may be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of these events will be archived for 30 days on the company's website.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
